Abstract
Elevated plasma levels of remnant lipoproteins and small, dense low-density lipoprotein (LDL) particles increase the risk of atherosclerosis. This prospective, placebo-controlled, crossover trial evaluated the effect of atorvastatin on various lipid parameters including remnant lipoproteins and small, dense-LDL cholesterol levels. Forty-five subjects were enrolled in the study. These subjects fell into three distinct lipid patterns: atherogenic dyslipidemia, isolated hypercholesterolemia, and mixed dyslipidemia. Regardless of the baseline lipid profile, atorvastatin (10 mg q x d) reduced levels of remnant lipoproteins by 25%, LDL-cholesterol by 27%, and the three LDL subfractions by 23%-28% (p
| Original language | English (US) |
|---|---|
| Pages (from-to) | 154-160 |
| Number of pages | 7 |
| Journal | Preventive Cardiology |
| Volume | 7 |
| Issue number | 4 |
| State | Published - Sep 2004 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Public Health, Environmental and Occupational Health
Cite this
Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern. / O'Keefe, James H.; Captain, Becky K.; Jones, Philip G.; Harris, William.
In: Preventive Cardiology, Vol. 7, No. 4, 09.2004, p. 154-160.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern.
AU - O'Keefe, James H.
AU - Captain, Becky K.
AU - Jones, Philip G.
AU - Harris, William
PY - 2004/9
Y1 - 2004/9
N2 - Elevated plasma levels of remnant lipoproteins and small, dense low-density lipoprotein (LDL) particles increase the risk of atherosclerosis. This prospective, placebo-controlled, crossover trial evaluated the effect of atorvastatin on various lipid parameters including remnant lipoproteins and small, dense-LDL cholesterol levels. Forty-five subjects were enrolled in the study. These subjects fell into three distinct lipid patterns: atherogenic dyslipidemia, isolated hypercholesterolemia, and mixed dyslipidemia. Regardless of the baseline lipid profile, atorvastatin (10 mg q x d) reduced levels of remnant lipoproteins by 25%, LDL-cholesterol by 27%, and the three LDL subfractions by 23%-28% (p
AB - Elevated plasma levels of remnant lipoproteins and small, dense low-density lipoprotein (LDL) particles increase the risk of atherosclerosis. This prospective, placebo-controlled, crossover trial evaluated the effect of atorvastatin on various lipid parameters including remnant lipoproteins and small, dense-LDL cholesterol levels. Forty-five subjects were enrolled in the study. These subjects fell into three distinct lipid patterns: atherogenic dyslipidemia, isolated hypercholesterolemia, and mixed dyslipidemia. Regardless of the baseline lipid profile, atorvastatin (10 mg q x d) reduced levels of remnant lipoproteins by 25%, LDL-cholesterol by 27%, and the three LDL subfractions by 23%-28% (p
UR - http://www.scopus.com/inward/record.url?scp=16544369296&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16544369296&partnerID=8YFLogxK
M3 - Article
C2 - 15539961
AN - SCOPUS:16544369296
VL - 7
SP - 154
EP - 160
JO - Preventive Cardiology
JF - Preventive Cardiology
SN - 1520-037X
IS - 4
ER -